RU2012101995A - Фармацевтический агент - Google Patents

Фармацевтический агент Download PDF

Info

Publication number
RU2012101995A
RU2012101995A RU2012101995/15A RU2012101995A RU2012101995A RU 2012101995 A RU2012101995 A RU 2012101995A RU 2012101995/15 A RU2012101995/15 A RU 2012101995/15A RU 2012101995 A RU2012101995 A RU 2012101995A RU 2012101995 A RU2012101995 A RU 2012101995A
Authority
RU
Russia
Prior art keywords
spp
pharmaceutical agent
agent according
cytokine
inflammation
Prior art date
Application number
RU2012101995/15A
Other languages
English (en)
Russian (ru)
Inventor
Грегори СТОЛОФФ
Уилсон ВАНДЕРЛЕЙ
Original Assignee
Пептселл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0910754A external-priority patent/GB0910754D0/en
Priority claimed from GB0913956A external-priority patent/GB0913956D0/en
Priority claimed from GB0920790A external-priority patent/GB0920790D0/en
Application filed by Пептселл Лимитед filed Critical Пептселл Лимитед
Publication of RU2012101995A publication Critical patent/RU2012101995A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012101995/15A 2009-06-22 2010-06-22 Фармацевтический агент RU2012101995A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0910754.1 2009-06-22
GB0910754A GB0910754D0 (en) 2009-06-22 2009-06-22 Pharmaceutical agent
GB0913956.9 2009-08-10
GB0913956A GB0913956D0 (en) 2009-08-10 2009-08-10 Pharmaceutical agent
GB0920790.3 2009-11-27
GB0920790A GB0920790D0 (en) 2009-11-27 2009-11-27 Pharmaceutical agent
PCT/EP2010/058788 WO2010149641A2 (en) 2009-06-22 2010-06-22 Pharmaceutical agent

Publications (1)

Publication Number Publication Date
RU2012101995A true RU2012101995A (ru) 2013-07-27

Family

ID=42727542

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012101995/15A RU2012101995A (ru) 2009-06-22 2010-06-22 Фармацевтический агент

Country Status (10)

Country Link
US (1) US20120100155A1 (enExample)
EP (1) EP2424893A2 (enExample)
JP (1) JP2012530755A (enExample)
KR (1) KR20120044937A (enExample)
CN (1) CN102459339A (enExample)
AU (1) AU2010264764A1 (enExample)
BR (1) BRPI1013525A2 (enExample)
CA (1) CA2764257A1 (enExample)
RU (1) RU2012101995A (enExample)
WO (1) WO2010149641A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142387A1 (en) * 2012-03-19 2013-09-26 Cardiomems, Inc. Pulmonary arterial hemodynamic monitoring for chronic obstructive pulmonary disease assessment and treatment
WO2013179302A1 (en) 2012-05-15 2013-12-05 Rajesh Shah Oral anti-inflammatory formulation comprising potentised cytokine
EP2922465A4 (en) 2012-11-21 2016-07-06 Cardiomems Inc DEVICES, SYSTEMS AND METHODS FOR ASSESSING AND TREATING PULMONARY ARTERIAL HYPERTENSION (PAH)
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN111214495B (zh) * 2020-03-02 2021-12-31 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462454B2 (en) * 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
RU2332236C1 (ru) * 2007-02-02 2008-08-27 Олег Ильич Эпштейн Лекарственное средство для лечения гриппа у птиц
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy

Also Published As

Publication number Publication date
WO2010149641A2 (en) 2010-12-29
KR20120044937A (ko) 2012-05-08
AU2010264764A1 (en) 2011-12-08
EP2424893A2 (en) 2012-03-07
JP2012530755A (ja) 2012-12-06
WO2010149641A3 (en) 2011-02-24
CA2764257A1 (en) 2010-12-29
US20120100155A1 (en) 2012-04-26
BRPI1013525A2 (pt) 2016-04-05
CN102459339A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
RU2012101995A (ru) Фармацевтический агент
Barnes Cytokine modulators as novel therapies for airway disease
JP2012530755A5 (enExample)
Van Reeth Cytokines in the pathogenesis of influenza
JP2018009002A5 (enExample)
JP2017080507A5 (enExample)
Dias et al. Adamalysins in COVID-19–Potential mechanisms behind exacerbating the disease
WO2020231855A4 (en) Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
Xu et al. Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: an open prospective cohort study
CN115484964A (zh) 冠状病毒感染和相关细胞因子毒性的治疗
Abou Baker Can natural products modulate cytokine storm in SARS-CoV2 patients?
Nadimi Parashkouhi et al. The dual sides of interferon induction in COVID-19 treatment
Akbulut et al. Effect of COVID-19 pandemic on patients who have undergone liver transplantation because of hepatocellular carcinoma
JP2023526536A5 (enExample)
Ritchie et al. Viral infection
Kim et al. Respiratory Protective Effect of a RML on PM10D-induced Lung Injury Mouse Model
Varghese et al. Therapeutic plasma exchange using convalescent plasma replacement therapy in severe COVID-19 infections: a potential therapeutic option
Pekcan et al. Successful Therapy with intravenous gamma globulin in two children with postinfectious bronchiolitis obliterans
CN111228480A (zh) 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
谷憲治 et al. A case of sarcoidosis associated with chronic eosinophilic pneumonia
Jackson et al. Effects of GHRH-R Antagonist MIA-602 or Agonist MR-409 on Human iAT2 Cells Exposed to Cytokines or LPS
CN101057840A (zh) Vam3在制备治疗慢性阻塞性肺疾病的药物中的应用
CN105412112A (zh) Roquefortine F在制备治疗慢性阻塞性肺疾病药物中的应用
Cottin Idiopathic eosinophilic pneumonias
Bartlett et al. IL-25 Inhibits Airway Anti-Viral Immunity and Promotes Virus Exacerbation of Allergic Airways Disease